Ultragenyx
$ 22.75
1.07%
24 Feb - close price
- Market Cap 2,171,710,000 USD
- Current Price $ 22.75
- High / Low $ 23.00 / 22.42
- Stock P/E N/A
- Book Value -0.83
- EPS -5.83
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -6.08 %
- 52 Week High 43.54
- 52 Week Low 18.41
About
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.
Analyst Target Price
$56.55
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-11-06 | 2025-08-05 | 2025-05-06 | 2025-02-13 | 2024-11-05 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -1.29 | -1.81 | -1.17 | -1.57 | -1.39 | -1.4 | -1.52 | -2.03 | -1.52 | -2.23 | -2.25 | -2.33 |
| Estimated EPS | -1.15 | -1.21 | -1.32 | -1.64 | -1.27 | -1.47 | -1.69 | -1.73 | -1.62 | -2.08 | -2.07 | -1.98 |
| Surprise | -0.14 | -0.6 | 0.15 | 0.07 | -0.12 | 0.07 | 0.17 | -0.3 | 0.1 | -0.15 | -0.18 | -0.35 |
| Surprise Percentage | -12.1739% | -49.5868% | 11.3636% | 4.2683% | -9.4488% | 4.7619% | 10.0592% | -17.341% | 6.1728% | -7.2115% | -8.6957% | -17.6768% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.34 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RARE
2026-02-23 21:26:58
Ultragenyx (NASDAQ: RARE) announced its participation in three investor conferences in March 2026 to discuss its focus on novel therapies for rare genetic diseases. Eric Crombez, M.D., Chief Medical Officer, will represent the company, engaging in fireside chats and one-on-one meetings at the Cowen Healthcare Conference, Barclays Global Healthcare Conference, and Leerink Partners Global Biopharma Conference. Webcasts of the fireside chats will be available on the company's investor relations website for broader access.
2026-02-23 21:26:58
Ultragenyx Pharmaceutical Inc. announced its participation in three investor conferences in March 2026. Eric Crombez, M.D., Chief Medical Officer, will represent the company at the 46th Annual Cowen Healthcare Conference, the Barclays 28th Annual Global Healthcare Conference, and the Leerink Partners Global Biopharma Conference, participating in fireside chats and 1x1 meetings. The company focuses on developing and commercializing novel therapies for rare and ultra-rare genetic diseases.
2026-02-23 21:26:58
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Ultragenyx Pharmaceutical Inc. (RARE) on behalf of investors who purchased common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made misleading statements regarding its drug setrusumab and its Phase III Orbit study. Investors have until April 6, 2026, to seek lead plaintiff status.
2026-02-23 16:43:05
Ultragenyx Pharmaceutical Inc. shares rose after the FDA accepted its Biologics License Application for DTX401, a gene therapy for Glycogen Storage Disease Type Ia, granting it Priority Review. The FDA set an action date of August 23, 2026, for the potential approval of DTX401, which would be the first treatment to address the underlying cause of GSDIa. Clinical data showed patients treated with DTX401 experienced reductions in cornstarch intake, improved euglycemia, and enhanced quality of life.
2026-02-23 15:30:00
Ultragenyx Pharmaceutical Inc. announced that the U.S. FDA has accepted and granted Priority Review for its Biologics License Application (BLA) for DTX401 AAV gene therapy for Glycogen Storage Disease Type Ia (GSDIa). A PDUFA action date is set for August 23, 2026. If approved, DTX401 would be the first treatment to address the underlying cause of GSDIa, offering a significant improvement over current dietary management which places a substantial burden on patients and families.
2026-02-23 14:30:59
Robbins Geller Rudman & Dowd LLP has filed a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased common stock between August 3, 2023, and December 26, 2025. The lawsuit alleges that Ultragenyx made misleading statements regarding its setrusumab drug and the Phase III Orbit and Cosmic studies, which ultimately failed to meet their primary endpoints, causing significant stock price drops. Investors who suffered substantial losses have until April 6, 2026, to seek appointment as lead plaintiff.
